Mylan assures India it won’t dismiss domestic market with Agila buy

GP20 says: Will it become more challenging to acquire major international players if the domestic government is focused on protecting local markets? Both in terms of jobs and product distribution. A new consideration in an ever consolidation industry.

Mylan has let authorities in India know that if they approve its planned $1.6 billion deal to buy Strides Arcolab’s sterile injectables unit, Agila Specialties, it intends to more than triple the sterile injectable production aimed at the Indian market.

Read the source article at Pharma News